Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already …
RP Giugliano, A Keech, SA Murphy, K Huber… - JAMA …, 2017 - jamanetwork.com
Importance Current guidelines for atherosclerotic cardiovascular disease focus on high-
intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL …
intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial
SA Murphy, TR Pedersen, ZA Gaciong, R Ceska… - JAMA …, 2019 - jamanetwork.com
Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
Long-term low-density lipoprotein cholesterol–lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years …
MJ Koren, MS Sabatine, RP Giugliano… - JAMA …, 2017 - jamanetwork.com
Importance The Open-Label Study of Long-term Evaluation Against LDL-C (OSLER-1)
evaluated the durability of long-term efficacy and safety during long-term therapy with …
evaluated the durability of long-term efficacy and safety during long-term therapy with …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE
P Gaba, ML O'Donoghue, JG Park, SD Wiviott, D Atar… - Circulation, 2023 - Am Heart Assoc
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for
atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with …
atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with …
Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER
MS Sabatine, GM De Ferrari, RP Giugliano, K Huber… - Circulation, 2018 - Am Heart Assoc
Background: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein …
Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein …
Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia
MJ Koren, MS Sabatine, RP Giugliano… - Journal of the American …, 2019 - jacc.org
Background: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …
Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial
Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …